Details for New Drug Application (NDA): 061334
✉ Email this page to a colleague
NDA 061334 describes BACTOCILL, which is a drug marketed by Glaxosmithkline and Baxter Hlthcare and is included in six NDAs. Additional details are available on the BACTOCILL profile page.
The generic ingredient in BACTOCILL is oxacillin sodium. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the oxacillin sodium profile page.
The generic ingredient in BACTOCILL is oxacillin sodium. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the oxacillin sodium profile page.
Summary for 061334
| Tradename: | BACTOCILL |
| Applicant: | Glaxosmithkline |
| Ingredient: | oxacillin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 061334
Profile for product number 006
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Mar 26, 1982 | TE: | RLD: | No | |||||
Profile for product number 007
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Mar 26, 1982 | TE: | RLD: | No | |||||
Profile for product number 008
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 4GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Mar 26, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
